

# Andreas H Scheel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7297466/publications.pdf>

Version: 2024-02-01

19  
papers

1,240  
citations

840776

11  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	5.5	340
2	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	7.0	223
3	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	1.1	178
4	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	5.5	135
5	Overcoming EGFR T790M-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
6	Interlaboratory concordance of PD-L1 immunohistochemistry for non-small cell lung cancer. <i>Histopathology</i> , 2018, 72, 449-459.	2.9	71
7	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	55
8	Impact of updated HER2 testing guidelines in breast cancer – re-evaluation of HERA trial fluorescence in situ hybridization data. <i>Modern Pathology</i> , 2015, 28, 1528-1534.	5.5	47
9	Optimized PD-L1 scoring of gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 1115-1122.	5.3	25
10	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
11	Physical basis of the 4+ magnification rule™ for standardized immunohistochemical scoring of HER2 in breast and gastric cancer. <i>Diagnostic Pathology</i> , 2018, 13, 19.	2.0	15
12	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291.	2.6	7
13	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	2.0	6
14	High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome. <i>Cancers</i> , 2022, 14, 2084.	3.7	5
15	Optimized expression-based microdissection of formalin-fixed lung cancer tissue. <i>Laboratory Investigation</i> , 2017, 97, 863-872.	3.7	3
16	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	2
17	Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients. <i>Surgical Oncology</i> , 2021, 37, 101611.	1.6	2
18	High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. <i>ERJ Open Research</i> , 2021, 7, 00787-2020.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.. Journal of Clinical Oncology, 2022, 40, e21013-e21013.	1.6	0